Member Info for Propinquity

EB, Let's hope so - as I said in a post about a week ago: this one remains ironed and neatly folded in the cliched bottom drawer, ready to be worn to a box-office opening.

Intriguingly, in the second Youtube video of that post, about fourteen minutes in, Catha declares that he would be surprised if AMYT still existed as a company in eighteen months - confident of takeover, then, what with the drugs' pipeline bursting with products, trials, and approvals.

Shrewdy, Never thought I would see you writing your wisdom on this board.

Snickers, Excellent find; an interesting, confidence-building interview for us PIs - and, further proof that the board envisions a larger, successful and profitable company over the next few years, by a) developing and commercialising the current drugs for orphan-diseases, and b) over the longer term, presumably after establishing the maximum commcercial potential of the former, acquire other smaller companies with drugs in successful developmental stages that need investment in their final stages for approval, and commercialisation. Another potential Shire, perhaps; either way, one for the cliched bottom drawer.

Only a fool with a horse would befit such a location

Ant, Thanks for the time to post a sucinct, reassuring post, which should somewhat assuage those who may be wavering on the current and future merits of this metamorphosis from oil to pharma.

jmr - haha...insolvency would be caused by reverting to our wonderfully oily assets!

I had no idea CF expected us not to be around in eighteen months - a confidently positive implication of a much larger m'cap than now

More a long-term share than a daily- or weekly-action one. But when news starts, it may flow into a rapid - then, who knows what price this may be, say, next year. Suffice to say that the hackneyed phrase 'if you snooze, you lose' may not be applicable to this one in the short term.

Trader, Goodduck, Buysbadly, and Gilgamesh - I don't know about y'all, but I would like to remain invested for the next one or two years at the least: I think that's when the big-time multi-bagging will be commencing (if it's sooner, great; longer, I'll continue waiting).

Great news! A sizeable investor.

Trader, All anatomical digits are crossed - waiting for my first multi-bagger!

Thanks, Calimocho, an interesting read. The table on page 11 compares AMYT's valuation with that of its peers who possess products at similar stages - but, because its products are at phase II/III, then a truer comparison maybe with only two of those: Sage Therapeutics, with products in phase III, valued at £839m; and Ultragenyx, with products in phase II/III, valued at £1.99bn. The conclusion from just those comparisons may indicate an unfair undervaluation of AMYT, at about £50m; even if it reaches a market-cap of £250m, that will be a considerable increase - and, still grossly undervalued compared with its peers, particularly if its products are approved for medical use. Thoughts, anyone?

Short-term share-prices rarely reflect the long-term potential - and potentially consequent value - of a company with good management and well-developed products that fill gaps (medical, in this instance) in the market. As someone stated in an earlier post, this share is more about long- than short-term potential.

Ant, hit the nail on the head.

So, who are you - The Sage of Omaha?

Unconstructive hypothesis: the new venture in pharma may take time to flourish - but, as a few posters had previously posted on FAST's board, compared with its new peers, it's already grossly undervalued - and, despite a revenue from one of the products.

By name, By nature - thanks Early Bird; must remember not to type in 'FAST' when searching on AMYT. ;-)

Gilgamesh, Could not agree more; let's hope tomorrow's consolidation propitiously recommences for our new foray into pharma

Radar, Indeed, Friel takes a chance - a particularly large one, with probably a large part of his own fortune, but for which he would have undoubtedly scrutinised before committing potentially financial hari-kari. And, likewise, probably many of this board's posters' gambling varying amounts of their own cash, who, in all likelihood, would have researched the potential success of FAST's new venture. Ultimately, the risk-to-reward ratio seems to be favourable for the sticky investors; very few AIM stocks reveal as much potential, especially with as strongly a decorated Board.